Mindfulness to Improve Functional Outcomes in Patients With Fibromyalgia or Central Sensitization

Chronic pain has a substantial economic cost and rate of impairment. Patients who suffer from
fibromyalgia and other pain conditions leading to central sensitization have limited
treatment options. The only medications currently approved by the Food and Drug
Administration (FDA) for the treatment of fibromyalgia includes pregabalin, milnacipran and
duloxetine. The International Association for the Study of Pain (IASP) also recommends the
implementation of an exercise program and cognitive behavioral therapy. A previous
meta-analysis found weak evidence to support Mindfulness-Based Stress Reductions (MBSR) in
fibromyalgia patients, however more robust clinical studies are needed. In the midst of an
opioid crisis, MBSR provides a safer alternative for the treatment of chronic pain.
Unfortunately, an instructor lead MBSR program is both costly and largely unavailable in
rural areas of the country. This web-based mindfulness program provides a treatment option
for patients who would otherwise, not have access to alternative medicine therapies.

Inclusion Criteria:

- Age from 30-65

- Patients with a diagnosis of fibromyalgia or central sensitization for greater than 6
months who are referred to the Interventional Pain Clinic

Exclusion Criteria:

- Patients on greater than 120 morphine equivalents per day

- Patients with untreated psychological illness

- Patients already enrolled in ongoing trials involving pain management and treatment
interventions

- Patients currently undergoing treatment at the Osher Center for Integrative Health or
patients with previous or current training in mindfulness.